These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 30032296)

  • 41. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
    Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
    J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
    Rytelewski M; Maleki Vareki S; Mangala LS; Romanow L; Jiang D; Pradeep S; Rodriguez-Aguayo C; Lopez-Berestein G; Figueredo R; Ferguson PJ; Vincent M; Sood AK; Koropatnick JD
    Oncotarget; 2016 Apr; 7(15):20825-39. PubMed ID: 26959114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.
    Verma P; Zhou Y; Cao Z; Deraska PV; Deb M; Arai E; Li W; Shao Y; Puentes L; Li Y; Patankar S; Mach RH; Faryabi RB; Shi J; Greenberg RA
    Nat Cell Biol; 2021 Feb; 23(2):160-171. PubMed ID: 33462394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
    Trenner A; Godau J; Sartori AA
    Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
    Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
    Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.
    Rondinelli B; Gogola E; Yücel H; Duarte AA; van de Ven M; van der Sluijs R; Konstantinopoulos PA; Jonkers J; Ceccaldi R; Rottenberg S; D'Andrea AD
    Nat Cell Biol; 2017 Nov; 19(11):1371-1378. PubMed ID: 29035360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
    BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    Tsujino T; Takai T; Hinohara K; Gui F; Tsutsumi T; Bai X; Miao C; Feng C; Gui B; Sztupinszki Z; Simoneau A; Xie N; Fazli L; Dong X; Azuma H; Choudhury AD; Mouw KW; Szallasi Z; Zou L; Kibel AS; Jia L
    Nat Commun; 2023 Jan; 14(1):252. PubMed ID: 36650183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.
    Song L; McNeil EM; Ritchie AM; Astell KR; Gourley C; Melton DW
    BMC Cancer; 2017 Dec; 17(1):864. PubMed ID: 29254481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. BRCA2 promotes genomic integrity and therapy resistance primarily through its role in homology-directed repair.
    Lim PX; Zaman M; Feng W; Jasin M
    Mol Cell; 2024 Feb; 84(3):447-462.e10. PubMed ID: 38244544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
    Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
    Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
    Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmüller L
    Carcinogenesis; 2014 Oct; 35(10):2273-82. PubMed ID: 25085902
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
    Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
    Jian W; Xu HG; Chen J; Xu ZX; Levitt JM; Stanley JA; Yang ES; Lerner SP; Sonpavde G
    Anticancer Drugs; 2014 Sep; 25(8):878-86. PubMed ID: 24714082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.
    Kharat SS; Ding X; Swaminathan D; Suresh A; Singh M; Sengodan SK; Burkett S; Marks H; Pamala C; He Y; Fox SD; Buehler EC; Muegge K; Martin SE; Sharan SK
    Sci Signal; 2020 Aug; 13(645):. PubMed ID: 32817374
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
    Maeda J; Haskins JS; Kato TA
    Mutat Res; 2023; 826():111815. PubMed ID: 36812659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.